/ Home / Product Center / Advance Intermediates / Anti-Cancer /

Ruxolitinib Intermediate

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CAS
941678-49-5
MF
C17H18N6
MW
306.37
Purity
98%
Indication
Ruxolitinib Intermediate
Description

In November 2011, the U.S. FDA approved ruxolitinib (INCB018424) for the treatment of patients with intermediate or high-risk myelofibrosis. Ruxolitinib is an ATP-competitive inhibitor of JAK1 and JAK2 (IC50's of 3.3±1.2 nM and 2.8±1.2 nM